Analytical Data
-
Gene name
CHRNa2
- Application
-
Alternative Names
CHR-NA2; CHRN-A2; N-AChRA2; NAChRA2; N-AChR-A2; Neuronal Acetylcholine Receptor Alpha 2
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q91X60
-
Expression Region
Gln28~Leu241
-
Molecular Weight
29kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Cholinergic receptors, particularly the nicotinic acetylcholine receptor (nAChR), play a crucial role in neurotransmission and are implicated in various physiological and pathological processes. Among the different subtypes, the alpha2 (CHRNa2) subunit is of particular interest due to its involvement in neurodevelopment and neurotransmitter release modulation. Research has shown that CHRNa2 can influence synaptic plasticity and cognitive function, making it a potential target for therapeutic interventions in neurological disorders such as Alzheimer's disease, schizophrenia, and addiction. Additionally, the production of recombinant CHRNa2 proteins allows for detailed structural and functional analyses, facilitating our understanding of receptor dynamics and pharmacological profiles. Studies focusing on the CHRNa2 subunit aim to elucidate its role in receptor oligomerization, ligand-binding affinity, and signal transduction mechanisms. As researchers explore the structural biology of CHRNa2 through techniques like X-ray crystallography and cryo-electron microscopy, the insights gained could lead to the development of more effective drugs that selectively target this receptor subtype, enhancing therapeutic strategies for various neuropsychiatric conditions.
